Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PORTIA-21 vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oral contraceptive: inhibition of ovulation by suppressing gonadotropin release; increases viscosity of cervical mucus, reducing sperm penetration; alters endometrial receptivity.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy,Hormonal contraceptive (off-label: menstrual regulation, acne, hirsutism)
Prevention of pregnancy (FDA-approved)
One tablet (norgestimate 0.180 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 days, followed by 7 days of placebo.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Terminal elimination half-life: 24-30 hours; clinical context: steady-state reached after 5-7 days, allows once-daily dosing
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Ethinyl estradiol undergoes first-pass metabolism in liver and gut via CYP3A4; levonorgestrel metabolized via CYP3A4 and reduction/sulfation.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal (50-60% unchanged), fecal (30-40% as metabolites), minor biliary
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
98-99% bound, primarily to albumin and sex hormone-binding globulin (SHBG)
~99% bound to serum albumin and sex hormone-binding globulin.
2.8-4.1 L/kg, indicating extensive tissue distribution and accumulation in fat and reproductive organs
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: 60-80% (first-pass metabolism reduces systemic availability); IV: 100%
Oral: ~70% due to first-pass metabolism.
No dose adjustment required for mild to moderate renal impairment. Insufficient data for severe renal impairment (e GFR <30 m L/min/1.73 m²); use with caution.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in Child-Pugh class B or C (moderate to severe hepatic impairment). For Child-Pugh class A, use with caution; no specific dose adjustment recommended.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily for 21 days, then 7 days placebo).
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for postmenopausal women. No specific geriatric dosing recommendations; follow standard dosing if prescribed off-label, but consider increased risk of thromboembolism and cardiovascular events.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events from combination hormonal contraceptives. Risk increases with age (especially >35) and number of cigarettes smoked. Women >35 who smoke should not use this product.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Increased risk of thromboembolic disorders,Elevated blood pressure,Hepatic neoplasia or active liver disease,Gallbladder disease,Carbohydrate/lipid effects,Ocular changes (retinal thrombosis),Headache/migraine,Menstrual irregularities
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Thrombophlebitis or thromboembolic disorders,History of deep vein thrombosis or pulmonary embolism,Cerebrovascular or coronary artery disease,Known or suspected breast cancer,Carcinoma of endometrium or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No specific food interactions are known. Grapefruit juice may increase estrogen levels but not clinically significant; no dietary restrictions required. Take with food or milk if nausea occurs.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
Pregnancy category X. Contraindicated in pregnancy. First trimester: Major congenital anomalies including cardiovascular, skeletal, and neural tube defects due to progestin and estrogen exposure. Second and third trimesters: Increased risk of fetal genital abnormalities, urogenital malformations, and potential long-term effects on reproductive development. Use only if pregnancy is ruled out.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Excreted in human milk. M/P ratio not established. May reduce milk production and composition. Potential for adverse effects in the nursing infant including jaundice, breast enlargement, and hormonal disruption. Use is contraindicated during breastfeeding.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
No safe dose in pregnancy. Contraindicated and should be discontinued immediately if pregnancy occurs. No dose adjustment possible due to teratogenicity.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
Portia-21 (oral contraceptive pill containing levonorgestrel and ethinyl estradiol) requires strict adherence to a daily schedule; missed pills increase ovulation risk. First dose should be taken on the first day of menstruation for immediate contraceptive effect. Counsel patients that breakthrough bleeding is common in initial cycles but usually resolves. Concomitant use with CYP3A4 inducers (e.g., rifampin, St. John's wort) reduces efficacy and requires alternative contraception. Monitor blood pressure and consider increased thrombotic risk in smokers over age 35.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one pill at the same time every day, even if you do not have sex that day.,If you miss a pill, refer to the package insert instructions; use backup contraception for 7 days if late by more than 12 hours.,Breakthrough spotting or nausea may occur initially but often improves; do not stop taking the pill.,Tell your doctor about all medications, including over-the-counter drugs and herbal supplements.,Smoking while taking this pill increases risk of blood clots, especially if over 35 years old.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PORTIA-21 vs AFIRMELLE, answered by our medical review team.
PORTIA-21 is a Oral Contraceptive that works by Oral contraceptive: inhibition of ovulation by suppressing gonadotropin release; increases viscosity of cervical mucus, reducing sperm penetration; alters endometrial receptivity.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PORTIA-21 and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PORTIA-21 is: One tablet (norgestimate 0.180 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 days, followed by 7 days of placebo.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PORTIA-21 and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PORTIA-21 is classified as Category C. Pregnancy category X. Contraindicated in pregnancy. First trimester: Major congenital anomalies including cardiovascular, skeletal, and neural tube defects due to progestin and est. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.